A South Korean study by S.-W. Jung et al titled “Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study” published on 23 July 2024 reveals what should already be known had any half-decent clinical trial was conducted for the so-called vaccine.
The study includes over 9.2 million individuals who had received at least one dose of the mRNA COVID-19 “vaccine”. One of the problems is that the South Korean population is so highly vaccinated that there are not enough unvaccinated individuals to form the unvaccinated control group, so the “observational period was shifted back 2 years from the date of the first dose of mRNA vaccination of the historical control cohort”.
The vaccination cohort and the historical vaccination cohort each had approximately 4.44 million individuals and the observational period was 365 days. Although this is longer than other studies, the authors admit that longer studies are required since “AI-CTDs can take years to decades after trigger exposure”.
Vaccinated individuals mostly did not have a higher risk of autoimmune connective tissue diseases (AI-CTDs). However, two conditions were notably worse for the vaccinated: bullous pemphigoid (BP) (aHR, 1.53; 99% CI, 0.90–2.60) and systemic lupus erythematosus (SLE) (aHR, 1.16; 99% CI, 1.02–1.32).
As for subgroups,
…women who had received the mRNA vaccine had a significantly higher risk of developing BP (aHR, 2.67; 99% CI, 1.11–6.42). In addition, aged ≥ 40 years who had undergone mRNA vaccination tended to have a higher risk of developing BP (aHR, 1.53; 99% CI, 0.90–2.61).
Individuals who received Pfizer
…had a significantly higher risk of developing SLE (aHR, 1.18; 99% CI, 1.02–1.36).
The study also mentioned myocarditis (aHR, 7.20; 99% CI, 4.37–11.86), pericarditis (aHR, 2.75; 99% CI, 1.95–3.88) and Gillian-Barre syndrome (aHR, 1.62; 99% CI, 1.16–2.25), all of which are significantly worse for the vaccinated.
Even though there mostly is little difference between the vaccinated and unvaccinated within the study period, an interesting observation was made for those who had received a booster (third dose):
In total, 2,284,342 individuals had the booster mRNA vaccination (3rd dose of mRNA vaccination) among the vaccination cohort. In extended Cox proportional hazard analyses treating booster vaccination as time-varying covariate, the risk of alopecia areata (aHR, 1.12; 99% CI, 1.05–1.19), psoriasis (aHR, 1.16; 99% CI, 1.06–1.27), and rheumatoid arthritis (aHR, 1.14; 99% CI, 1.08–1.21) were greater in individuals who had booster vaccination compared to those who had not.
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!
Kommentare